Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Svetomir Markovic, M.D

Hematology Rochester, MN Male

NPI: 1013981257

Total Payments

$7,687

2024 Payments

$2,409

Companies

Transactions

Medicare Patients

1,378

Medicare Billing

$603,153

Payment Breakdown by Category

Research$6,455 (84.0%)

Travel$1,206 (15.7%)

Food & Beverage$14.57 (0.2%)

Education$12.00 (0.2%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Unspecified	$6,455	3	84.0%
Travel and Lodging	$1,206	4	15.7%
Food and Beverage	$14.57	2	0.2%
Education	$12.00	1	0.2%

Payments by Type

Research

$6,455

3 transactions

General

$1,232

7 transactions

Top Paying Companies

Company	Total	Records	Latest Year
Novartis Pharmaceuticals Corporation	$6,467	4	$0 (2024)
E.R. Squibb & Sons, L.L.C.	$1,220	6	$0 (2019)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$2,409	2	Novartis Pharmaceuticals Corporation ($2,409)
2023	$4,045	1	Novartis Pharmaceuticals Corporation ($4,045)
2022	$12.00	1	NOVARTIS PHARMACEUTICALS CORPORATION ($12.00)
2019	$1,220	6	E.R. Squibb & Sons, L.L.C. ($1,220)

All Payment Transactions

10 individual payment records from CMS Open Payments

Date	Company	Product	Nature	Form	Amount	Type
07/11/2024	Novartis Pharmaceuticals Corporation	MEKINIST (Drug)	—	Cash or cash equivalent	$1,204.72	Research
Study: HEOR • Category: Oncology
06/04/2024	Novartis Pharmaceuticals Corporation	—	—	Cash or cash equivalent	$1,204.72	Research
Study: HEOR
05/10/2023	Novartis Pharmaceuticals Corporation	TAFINLAR (Drug), MEKINIST	—	Cash or cash equivalent	$4,045.33	Research
Study: TMT-AB -113851-Relapse-Free Survival with Adjuvant Dabrafenib/Trametinib Therapy After Relapse on Adjuvant Checkpoint Inhibitor Therapy and Subsequent Surgical Resection in Patients with BRAF V600-mutated Stage III/IV Melanoma: Interim Analysis-ESMO • Category: Oncology
05/11/2022	NOVARTIS PHARMACEUTICALS CORPORATION	TAFINLAR (Drug)	Education	In-kind items and services	$12.00	General
Category: ONCOLOGY
09/06/2019	E.R. Squibb & Sons, L.L.C.	—	Travel and Lodging	Cash or cash equivalent	$517.24	General
09/06/2019	E.R. Squibb & Sons, L.L.C.	—	Travel and Lodging	Cash or cash equivalent	$336.79	General
09/06/2019	E.R. Squibb & Sons, L.L.C.	—	Travel and Lodging	Cash or cash equivalent	$168.40	General
09/06/2019	E.R. Squibb & Sons, L.L.C.	—	Food and Beverage	Cash or cash equivalent	$10.36	General
09/06/2019	E.R. Squibb & Sons, L.L.C.	—	Food and Beverage	Cash or cash equivalent	$4.21	General
09/05/2019	E.R. Squibb & Sons, L.L.C.	—	Travel and Lodging	Cash or cash equivalent	$183.40	General

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
TMT-AB -113851-Relapse-Free Survival with Adjuvant Dabrafenib/Trametinib Therapy After Relapse on Adjuvant Checkpoint Inhibitor Therapy and Subsequent Surgical Resection in Patients with BRAF V600-mutated Stage III/IV Melanoma: Interim Analysis-ESMO	Novartis Pharmaceuticals Corporation	$4,045	1
HEOR	Novartis Pharmaceuticals Corporation	$2,409	2

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	3	81	126	$42,287	$10,436
2022	9	219	744	$101,791	$22,072
2021	21	603	11,682	$1.0M	$306,119
2020	14	475	8,183	$773,654	$264,525

Total Patients

1,378

Total Services

20,735

Medicare Billing

$603,153

Procedure Codes

All Medicare Procedures & Services

47 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99214	Established patient office or other outpatient visit, 30-39 minutes	Office	2023	50	85	$24,650	$8,042	32.6%
96413	Administration of chemotherapy into vein, 1 hour or less	Office	2023	19	20	$14,760	$2,132	14.4%
96375	Injection of additional new drug or substance into vein	Office	2023	12	21	$2,877	$262.60	9.1%
99214	Established patient office or other outpatient visit, 30-39 minutes	Office	2022	53	98	$28,420	$9,571	33.7%
96413	Administration of chemotherapy into vein, 1 hour or less	Office	2022	45	59	$42,067	$6,658	15.8%
99215	Established patient office or other outpatient visit, 40-54 minutes	Office	2022	15	15	$6,675	$2,019	30.3%
99204	New patient office or other outpatient visit, 45-59 minutes	Office	2022	11	11	$5,040	$1,468	29.1%
96417	Administration of additional new drug or substance into vein, 1 hour or less	Office	2022	12	21	$7,098	$1,158	16.3%
96375	Injection of additional new drug or substance into vein	Office	2022	25	49	$6,468	$641.02	9.9%
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	Office	2022	15	21	$3,948	$519.61	13.2%
J1100	Injection, dexamethasone sodium phosphate, 1 mg	Office	2022	19	214	$804.60	$19.91	2.5%
J2405	Injection, ondansetron hydrochloride, per 1 mg	Office	2022	24	256	$1,271	$17.26	1.4%
J9271	Injection, pembrolizumab, 1 mg	Office	2021	29	6,604	$912,411	$259,430	28.4%
96413	Infusion of chemotherapy into a vein up to 1 hour	Office	2021	108	123	$22,590	$14,491	64.1%
99214	Established patient outpatient visit, total time 30-39 minutes	Office	2021	56	116	$15,909	$11,762	73.9%
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	Office	2021	13	68	$24,615	$9,240	37.5%
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l	Office	2021	13	16	$2,352	$1,910	81.2%
96417	Infusion of different chemotherapy drug or substance into a vein up to 1 hour	Office	2021	29	32	$3,072	$1,749	56.9%
96375	Injection of different drug or substance into a vein for therapy, diagnosis, or prevention	Office	2021	60	119	$2,252	$1,633	72.5%
96367	Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour	Office	2021	30	56	$1,941	$1,454	74.9%
96415	Infusion of chemotherapy into a vein	Office	2021	28	44	$1,756	$1,117	63.6%
J1453	Injection, fosaprepitant, 1 mg	Office	2021	16	2,550	$2,240	$676.80	30.2%
J0640	Injection, leucovorin calcium, per 50 mg	Office	2021	13	234	$4,157	$621.65	15.0%
96402	Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle	Office	2021	21	23	$759.69	$616.87	81.2%
J2469	Injection, palonosetron hcl, 25 mcg	Office	2021	17	210	$2,381	$349.79	14.7%

1 2 »

About Dr. Svetomir Markovic, M.D

Dr. Svetomir Markovic, M.D is a Hematology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013981257.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Svetomir Markovic, M.D has received a total of $7,687 in payments from pharmaceutical and medical device companies, with $2,409 received in 2024. These payments were reported across 10 transactions from 2 companies. The most common payment nature is "" ($6,455).

As a Medicare-enrolled provider, Markovic has provided services to 1,378 Medicare beneficiaries, totaling 20,735 services with total Medicare billing of $603,153. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Hematology
Other Specialties Medical Oncology
Location Rochester, MN
Active Since 02/15/2006
Last Updated 08/18/2020
Taxonomy Code 207RH0000X
Entity Type Individual
NPI Number 1013981257

Products in Payments

TAFINLAR (Drug) $4,057
MEKINIST (Drug) $1,205

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.